Susceptibility to Infections in Patients With Ataxia Telangiectasia : A Prospective Follow-up Study
The study conducted by Johann Wolfgang Goethe University Hospital aims to elucidate the incidence and severity of respiratory infections in patients with Ataxia Telangiectasia (A-T) compared to healthy controls. Given the rarity of severe infections despite immunodeficiency, the findings may influence treatment paradigms regarding immunoglobulin replacement therapy in A-T patients. The collaboration with CSL Behring, a leader in immunotherapy, suggests potential interest in developing targeted therapies or supportive care strategies for A-T. The market for A-T treatments is niche but could expand if new therapeutic approaches are validated. The results may also impact competitive positioning for companies involved in immunotherapy and rare disease management.
Indication: Ataxia Telangiectasia
Modality: protein therapy
Target: ATM gene (Ataxia Telangiectasia Mutated gene) involved in cell cycle control and apoptosis.
Sponsor: Johann Wolfgang Goethe University Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: ATM gene (Ataxia Telangiectasia Mutated gene) involved in cell cycle control and apoptosis.
View original source fields
Condition raw: Ataxia Telangiectasia, Infections, Immunodeficiency, Lung Disease
Condition normalized: Ataxia Telangiectasia, Infections, Immunodeficiency, Lung Disease
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: ATM gene (Ataxia Telangiectasia Mutated gene) involved in cell cycle control and apoptosis.
Target normalized: ATM gene (Ataxia Telangiectasia Mutated gene) involved in cell cycle control and apoptosis.